What is the 52 Week High and Low of Concord Biotech Share Price?

The 52 week high and low prices of Concord Biotech share price is 2146 & 987. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Concord Biotech Share price

Q: How to buy Concord Biotech Share at Choice?

To buy Concord Biotech stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Concord Biotech, choose your preferred order type, and place the trade.

CONCORDBIO

Healthcare Large Cap

1347.5

7.50 (0.56%)

NSE

BSE

Last updated on 18 Jun, 2026 | 15:31 IST

BuySell

Today's High

1374.20

Today's Low

1336.70

52 Week Low

987.00

52 Week High

2146.00

Concord Biotech Chart

ChartIQ

TradingView

Concord Biotech Share Key Metrics

Volume

2.01 L

Market Cap

14097.03 CR

LTQ@LTP

5@1347.50

ATP

1353.21

Var Margin

21.19 %

Circuit Range

1072-1608

Delivery %

54.26 %

Value

27.22 CR

ASM/GSM

No

Market Lot

1

Summary

Concord Biotech share price is ₹1347.5 as of 19 Jun, 2026. The stock Concord Biotech intraday movement has stayed between ₹1336.70 and ₹1374.20, while on a 52-week basis,Concord Biotech price 52 week high is ₹2146.00 & its 52 week low is ₹987.00.

In terms of trading activity, Concord Biotech has recorded a volume of 201177 shares, The Concord Biotech has a market cap of ₹104616204 CR. The stock’s Average Traded Price (ATP) stands at ₹1353.21, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 5 @ ₹1347.50.

Concord Biotech operates within a circuit range of ₹1072.00 – ₹1608.00, with a Value of ₹27.22 CR. The Delivery Percentage for the day is 54.26%. Additionally, Concord Biotech currently falls under the No framework, and trades with a market lot size of 1.

Concord Biotech Fundamentals

P/E Ratio

53.76

P/B Ratio

6.95

Div. Yield

0.56

Sector P/E

69.55

Sector P/B

3.03

Sec. Div. Yield

0.54

Concord Biotech Resistance and Support

Pivot 1353.9

Resistance

First Resistance

1370.5

Second Resistance

1401

Third Resistance

1417.6

Support

First Support

1323.4

Second Support

1306.8

Third Support

1276.3

Concord Biotech Shareholding Pattern

2024-25
2025-26
2026-27
2023-24

Total Promoters

Segment

Percent

Total Promoters

44.08%

Mutual Fund

4.44%

Insurance

4.11%

Foreign Institutional Investors

7.58%

Domestic Institutional Investors

1.02%

Retail

38.77%

Others

0%

Total Promoters

MAR '25

44.08%

JUN '25

44.08%

SEP '25

44.08%

DEC '25

44.08%

Concord Biotech Corporate Actions

Date	Agenda
2026-05-29	Audited Results & Final Dividend
2026-02-11	Quarterly Results
2025-11-13	Quarterly Results
2025-08-08	Quarterly Results
2025-05-29	Audited Results & Final Dividend
2025-02-13	Quarterly Results

Concord Biotech News

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Concord Biotech will conduct virtual meetings with analysts and institutional investors on June 17, 2026, starting 10:30 am. No unpublished price sensitive information will be discussed.

Jun 13 2026 11:12:03

Concord Biotech Ltd - 543960 - Completion Of ANVISA Inspection Conducted By The Brazilian Health Regulatory Agency At The Limbasi API Manufacturing Facility

Concord Biotech successfully completed an ANVISA inspection by the Brazilian Health Regulatory Agency at its Limbasi API manufacturing facility. This strengthens its global regulatory footprint and supports international expansion.

Jun 12 2026 13:30:23

Concord Biotech Ltd - 543960 - Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Tofacitinib Tablets, 5 Mg And 10 Mg

Concord Biotech secured USFDA approval for its Tofacitinib Tablets (5mg & 10mg), opening access to an estimated US$500 million market in the U.S. This approval enhances the company's product offerings and supports its long-term growth strategy.

Jun 10 2026 10:08:29

Concord Biotech Ltd - 543960 - Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Mycophenolate Mofetil For Oral Suspension USP, 200 Mg/Ml

Concord Biotech received USFDA approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This expands the company's product offerings and provides access to an estimated US$30 million U.S. market, supporting long-term growth.

Jun 02 2026 16:34:47

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Concord Biotech successfully held its Q4 FY26 earnings call, discussing the audited financial results for the quarter and full financial year ended March 31, 2026. The audio recording of this call is now available on the company's website.

Jun 01 2026 18:07:18

Concord Biotech Ltd - 543960 - Corporate Action-Board approves Dividend

Concord Biotech's board recommended a final dividend of ₹7.55 per equity share for FY26. The record date for the dividend payout is July 24, 2026, pending shareholder approval.

May 29 2026 21:18:25

Concord Biotech Ltd - 543960 - Board Meeting Intimation for Meeting To Be Held On Friday, May 29, 2026 Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Concord Biotech's Board of Directors will hold a meeting on May 29, 2026. The agenda includes the consideration and approval of the audited Q4 and full financial year 2026 results and a recommendation for a final dividend.

May 23 2026 10:36:30

Name	Position
Sudhir Vaid	Chairman & Managing Director
Ankur Vaid	Joint Managing Director & CEO

Concord Biotech Similar Stocks

Jubilant Pharmova Ltd.

973.45

-20.55 (2.07%)

Poly Medicure Ltd.

1573.20

35.60 (2.32%)

Natco Pharma Ltd.

883.50

16.40 (1.89%)

Alembic Pharmaceuticals Ltd.

749.70

3.55 (0.48%)

Rainbow Children's Medicare Ltd.

1450.00

5.50 (0.38%)

Dr. Agarwal's Health Care Ltd.

444.80

1.60 (0.36%)

Vijaya Diagnostic Centre Ltd.

1305.60

6.10 (0.47%)

Alivus Life Sciences Ltd.

1060.00

9.00 (0.86%)

Park Medi World Ltd.

255.25

1.10 (0.43%)

Sanofi Consumer Healthcare India Ltd.

4948.60

195.30 (4.11%)

Concord Biotech FAQs

The Buying Price of Concord Biotech share is 1347.5 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Concord Biotech stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Concord Biotech, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Concord Biotech shares is 53.76. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Concord Biotech shares is 6.95. Useful to assess the stock's value relative to its book value.

To assess Concord Biotech’s valuation compare Sector P/E, P/B which are 69.55 & 3.03 with sector averages, along with growth rates and financial metrics.

The Market Cap of Concord Biotech is 14097.03 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Concord Biotech share price is 2146.00 & 987.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Concord Biotech belongs to the Healthcare sector.